Korea's wearable robot makers compared: WIRobotics, Angel Robotics, Hurotics and Dynamic Solution, and why the money is moving toward humanoids

Among the Korean wearable and rehabilitation robot makers MEKAWIRE tracks, the two largest private rounds both came in 2026, and the larger one went to a company that is pivoting toward humanoids. That changes how investors and buyers should read the category: wearables are being valued partly as data and actuator platforms rather than as medical devices alone.

For hospitals and public buyers the practical consequence is that product roadmaps may shift. A supplier that raises on a humanoid story will allocate engineers and capital accordingly, and service and reimbursement work can lose priority.

WIRobotics has the strongest unit and revenue trajectory among private makers and the largest round, but also the most execution risk because it is running two product lines. Angel Robotics has the most mature commercial channel (hospitals, procurement, four brands) and public-market discipline, but smaller recent capital.

Hurotics is the most focused medical play, with US FDA listing and Korean Class II certification, and its reported Series A would put it close to Angel's private-round total. Dynamic Solution is pre-commercial, and its brain-computer-interface approach serves a narrower, higher-acuity patient group.

No private valuation is disclosed for WIRobotics or Hurotics, so the only priced reference is Angel Robotics' KOSDAQ listing at KRW 20,000 per share in March 2024. WIRobotics' Series B at 34 times trailing revenue implies investors are pricing future humanoid revenue, not the wearable run-rate.

Against global humanoid rounds in MEKAWIRE's database, which run to hundreds of millions of dollars, Korean wearable rounds remain small; the gap is the opportunity investors cite and the risk if the humanoid pivot stalls.

All four companies depend on compact actuators, motor drivers, batteries and sensing, much of it built in-house: Angel sells its own motor drivers and smart actuators under angel KIT, Hurotics uses tendon-driven soft actuation, and WIRobotics says its control technology carries over from WIM to ALLEX.

The overlap with humanoid supply chains is the strategic point: the same reducers, motors and force-control know-how serve both, so Korean component makers such as actuator and reducer suppliers stand to benefit from either path.

Angel Robotics' third-quarter report, due by mid-November under Korean disclosure rules, for procurement-driven revenue. WIRobotics' first Mobile ALLEX deliveries to outside institutions, promised for 2026.

Hurotics' own confirmation of its Series A and any US distribution agreement. A peer-reviewed publication of Dynamic Solution's X-hand results, which would turn a company claim into clinical evidence.

Thesis: investors are paying for wearable makers' movement data and actuator know-how as a route into humanoids. Confidence: medium. The WIRobotics release states the humanoid priority plainly, but one round is a small sample and Hurotics' reported raise points the other way.

We would raise confidence if another Korean wearable maker announces a humanoid or manipulation programme within six months, and lower it if Angel's procurement revenue grows faster than WIRobotics' total revenue.

For WIRobotics: what share of Series B proceeds goes to ALLEX versus WIM, and does WIM revenue alone cover its own costs? For Angel Robotics: how much revenue has the PPS Top Tier selection produced, and what is the reimbursement status of Angel Legs M20?

For Hurotics: when will the company confirm the Series A terms, and who will distribute H-Medi in the US? For Dynamic Solution: when will the X-hand clinical data from Charite and Seoul National University Bundang Hospital be published?